Antibiotic Resistance

Jeremy Lefroy Excerpts

Wednesday 15th October 2014 Westminster Hall

[Julian Sturdy]

I agree. Although I was only going to touch on that matter briefly, that does not mean that I do not recognise the impact on resistance from use of antibiotics in veterinary medicine. My right hon. Friend is right to mention the problems relating to resistance in the US, especially because the way that veterinary antibiotics are used there is quite frightening. In the UK and Europe, we use antibiotics differently. The Dutch are the example in that regard, and we have to learn from that. If we continue to misuse antibiotics, whether in human medicine or in the veterinary industry, resistance is bound to happen and that is bound to cause a problem, so we have to tackle it on both sides, although I want to focus on the human medicine side.

[Jeremy Lefroy (Stafford) (Con)]

My hon. Friend mentioned malaria and the treatments against it that have been discovered. He may know that, through misuse of the latest generation of artemisinin-based antimalarials, resistance to those is already coming up through Thailand and Burma and will possibly, eventually, get to sub-Saharan Africa, with devastating consequences, as was the case with previous antimalarials.

[Julian Sturdy]

My hon. Friend is right. I was going to touch on that. Multi-resistance is widespread around the world. He mentions antimalarials, but resistance is also apparent in relation to tuberculosis and there is emerging resistance to the antibiotics of last resort—the so called super antibiotics—the carbapenems, which are not licensed for use in farm animals on the veterinary side. That resistance is causing real concern.

Returning to the livestock sector for a minute, there is a tendency among some sections of the intensive livestock industry, and even some Governments, to dismiss almost entirely the contribution to resistance by veterinary use of antibiotics. This is a dangerous path to take, because although antibiotic use in farm animals may not be the main driver of resistance in humans, it is a still an important contributor, and we must recognise that.

--- Later in debate ---

[Jeremy Lefroy (Stafford) (Con)]

I congratulate my hon. Friend the Member for York Outer (Julian Sturdy) on taking the lead in the debate, and in the House previously. I congratulate, too, hon. Members from all parties, on setting out the issues clearly.

I want to concentrate on the second action point set out by my hon. Friend—a global network. I shall take malaria as an example—I declare an interest as chair of the all-party group on malaria and neglected tropical diseases—and will speak about what happened when resistance to malaria drugs spread around the world in the 1980s and 1990s. The drug that was most effective until then for the standard treatment of malaria was chloroquine. Quinine was of course a last resort, but chloroquine was used by most people. Resistance cropped up, initially in south-east Asia, spreading throughout sub-Saharan Africa, until there was little that most people who caught malaria could do, besides hoping it would be effective. In many cases it was not.

A new class of drugs was discovered, based on artemisinin, and a network called Medicines for Malaria Venture was set up. The previous Government were instrumental in setting up and supporting it, and the present Government have continued substantial support for it. As a result, even in 2008 there was a reasonable antimalarial drug pipeline. A couple of days ago in this place I had the pleasure of launching our group’s 2014 report, which had some helpful financial support from the Medicines for Malaria Venture. The pipeline has grown substantially in the six years since 2008. It has been remarkable to see not only that drugs have been coming through the pipeline, but that four of the six most commonly effective antimalarials at present have resulted from the venture. That is an example of what can be done by a multinational network, with Britain taking the lead. I urge the Minister to consider such an approach for antibiotics.

The chief medical officer, among others, has rightly referred to antibiotic resistance as a threat equivalent to the threat from terrorism. We see our work in international development as a means to combat many of the sources of terrorism. Unemployment around the world is a breeding ground for people who want to peddle violent and hateful dogmas. Where people have no jobs, ISIL uses that as an excuse to commit terrible acts. Terrorism is a threat, and so is antibiotic resistance. The problem is a global one, and relates to the global public good. Dealing with it would help the poorest in the world more than anyone else, and we could easily justify using overseas development assistance funding from the Department for International Development, alongside commercial and public health service funding, to fund a network such as the one I described. I urge the Minister to take as broad as possible an approach when she considers what sources of funding could be used to confront the threat. It cannot be exaggerated.